Argenx in cancer drug licensing dealFor up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive … more ➔
Swiss biotech continues to do wellDespite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new … more ➔
Recipharm in €68m Mitim takeoverRecipharm remains on track for growth. The Swedish CDMO is acquiring Italian injectable beta lactam expert Mitim Srl. The takeover is worth €68.4m. more ➔
